Vancomycin
- Generic Name
- Vancomycin
- Brand Names
- Firvanq, Vancocin
- Drug Type
- Small Molecule
- Chemical Formula
- C66H75Cl2N9O24
- CAS Number
- 1404-90-6
- Unique Ingredient Identifier
- 6Q205EH1VU
- Background
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].
- Indication
Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
- Associated Conditions
- Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
- Associated Therapies
- -
Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation
- Conditions
- Interventions
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT01925066
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
Neonatal Suspected Sepsis Treated With Cefazolin or Vancomycin
- Conditions
- Interventions
- First Posted Date
- 2013-06-03
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- Hospital Italiano de Buenos Aires
- Target Recruit Count
- 109
- Registration Number
- NCT01867138
- Locations
- 🇦🇷
Hospital Italiano de Buenos Aires, Buenos Aires, Capital, Argentina
Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia
- First Posted Date
- 2013-03-28
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5271
- Registration Number
- NCT01819935
Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2013-03-28
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 96
- Registration Number
- NCT01820026
- Locations
- 🇮🇹
Manuela Merli, Rome, Italy
Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin
- Conditions
- Interventions
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Hartford Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT01818141
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
- Conditions
- Interventions
- First Posted Date
- 2013-03-15
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 660
- Registration Number
- NCT01811732
- Locations
- 🇺🇦
Melinta Investigational Site, Zaporizhzhia, Ukraine
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Target Recruit Count
- 215
- Registration Number
- NCT01792804
- Locations
- 🇳🇱
Amsterdam, Amsterdam, Netherlands
🇳🇱Tilburg, Tilburg, Netherlands
🇳🇱Diakonessenhuis Utrecht, Utrecht, Netherlands
A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System
- Conditions
- Interventions
- First Posted Date
- 2013-01-25
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Astellas Pharma Europe Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT01775397
- Locations
- 🇪🇸
H.U. Gregorio Maranon, Madrid, Spain
🇩🇪Universitätsklinikum, Essen, Germany
🇩🇪Charité, Berlin, Germany
Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- University Hospital, Tours
- Target Recruit Count
- 100
- Registration Number
- NCT01757236
- Locations
- 🇫🇷
CHRU de Tours, Tours, Indre et Loire, France
🇮🇹Azienda Opedaliera Universitaria San Maria della Misericordia, Udine, Italy
🇫🇷CHU de Nantes, Nantes, France
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 100
- Registration Number
- NCT01734694
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.